Avricore Health Yönetim

Yönetim kriter kontrolleri 3/4

Avricore Health CEO'su Hector Bremner, Oct2019 tarihinde atandı, in görev süresi 5.08 yıldır. in toplam yıllık tazminatı CA$ 321.44K olup, şirket hissesi ve opsiyonları dahil olmak üzere 67.2% maaş ve 32.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.62% ine doğrudan sahiptir ve bu hisseler € 153.46K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.4 yıl ve 5.4 yıldır.

Anahtar bilgiler

Hector Bremner

İcra Kurulu Başkanı

CA$321.4k

Toplam tazminat

CEO maaş yüzdesi	67.2%
CEO görev süresi	5.1yrs
CEO sahipliği	1.6%
Yönetim ortalama görev süresi	4.4yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Hector Bremner'un ücretlendirmesi Avricore Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CA$3k
Mar 31 2024	n/a	n/a	-CA$341k
Dec 31 2023	CA$321k	CA$216k	-CA$701k
Sep 30 2023	n/a	n/a	-CA$1m
Jun 30 2023	n/a	n/a	-CA$901k
Mar 31 2023	n/a	n/a	-CA$824k
Dec 31 2022	CA$261k	CA$168k	-CA$818k
Sep 30 2022	n/a	n/a	-CA$782k
Jun 30 2022	n/a	n/a	-CA$1m
Mar 31 2022	n/a	n/a	-CA$1m
Dec 31 2021	CA$258k	CA$150k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$2m
Dec 31 2020	CA$185k	CA$150k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$909k
Jun 30 2020	n/a	n/a	-CA$1m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	CA$78k	CA$76k	-CA$2m

Tazminat ve Piyasa: Hector 'nin toplam tazminatı ($USD 230.61K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 483.75K ).

Tazminat ve Kazançlar: Hector şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Hector Bremner (42 yo)

5.1yrs

Görev süresi

CA$321,442

Tazminat

Mr. Hector Bremner serves as Chief Executive Officer at Avricore Health Inc. since October 15, 2019 and has been its Director since April 2, 2020. He served as an Executive Vice-President of Branding, Stra...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hector Bremner	CEO & Director	5.1yrs	CA$321.44k	1.62% € 153.5k
Kiriaki Smith	CFO & Corporate Secretary	5.3yrs	CA$167.95k	0.82% € 77.1k
Rodger Seccombe	CTO & Director	3.6yrs	CA$321.44k	4.84% € 456.7k
Will Seccombe	Communications Advisor	3.7yrs	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

43yo

Ortalama Yaş

Deneyimli Yönetim: 8VP1 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hector Bremner	CEO & Director	4.6yrs	CA$321.44k	1.62% € 153.5k
Rodger Seccombe	CTO & Director	3.9yrs	CA$321.44k	4.84% € 456.7k
David Hall	Independent Chairman of the Board	8.8yrs	CA$81.43k	1.41% € 133.6k
Robert Sindelar	Independent Director	6.7yrs	CA$53.78k	0.88% € 82.8k
Alan Arnstein	Independent Director	7.6yrs	CA$53.78k	0.025% € 2.3k
Sherif Guorgui	Member of Advisory Board	5.4yrs	Veri yok	Veri yok
Philippe Ugnat	Member of Advisory Board	5.2yrs	Veri yok	Veri yok
Ray Chepsiuk	Member of Advisory Board	5.8yrs	Veri yok	Veri yok
Mark Zhou	Member of Advisory Board	5.7yrs	Veri yok	Veri yok
David Huston	Member of Advisory Board	5.4yrs	Veri yok	Veri yok
David Noshad	Member of Advisory Board	5.1yrs	Veri yok	Veri yok
Sotiris Antoniou	Member of Advisory Board	5.1yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 8VP1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Avricore Health Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

Avricore Health Inc. Announces Board Changes

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

High number of new directors

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

Recent updates

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 2Q 2022)

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

New 90-day high: €0.36

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş